- Home
- LPCN vs ERNA Comparison
LPCN vs ERNA Comparison
Compare LPCN & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- ERNA
- Stock Information
- Founded
- LPCN 1997
- ERNA 2018
- Country
- LPCN United States
- ERNA United States
- Employees
- LPCN N/A
- ERNA N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- ERNA Health Care
- Exchange
- LPCN Nasdaq
- ERNA Nasdaq
- Market Cap
- LPCN 16.1M
- ERNA 13.5M
- IPO Year
- LPCN N/A
- ERNA N/A
- Fundamental
- Price
- LPCN $3.00
- ERNA $1.92
- Analyst Decision
- LPCN Strong Buy
- ERNA
- Analyst Count
- LPCN 2
- ERNA 0
- Target Price
- LPCN $9.00
- ERNA N/A
- AVG Volume (30 Days)
- LPCN 29.3K
- ERNA 97.0K
- Earning Date
- LPCN 08-07-2025
- ERNA 08-12-2025
- Dividend Yield
- LPCN N/A
- ERNA N/A
- EPS Growth
- LPCN N/A
- ERNA N/A
- EPS
- LPCN N/A
- ERNA N/A
- Revenue
- LPCN $3,674,834.00
- ERNA $535,000.00
- Revenue This Year
- LPCN N/A
- ERNA N/A
- Revenue Next Year
- LPCN N/A
- ERNA N/A
- P/E Ratio
- LPCN N/A
- ERNA N/A
- Revenue Growth
- LPCN N/A
- ERNA 365.22
- 52 Week Low
- LPCN $2.68
- ERNA $1.75
- 52 Week High
- LPCN $7.61
- ERNA $39.38
- Technical
- Relative Strength Index (RSI)
- LPCN 40.07
- ERNA 36.78
- Support Level
- LPCN $3.10
- ERNA $1.88
- Resistance Level
- LPCN $3.39
- ERNA $2.13
- Average True Range (ATR)
- LPCN 0.18
- ERNA 0.12
- MACD
- LPCN -0.00
- ERNA 0.04
- Stochastic Oscillator
- LPCN 0.00
- ERNA 43.24
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.